HRP960315A2 - Preparations and methods for the treatment of t cell mediated diseases - Google Patents

Preparations and methods for the treatment of t cell mediated diseases Download PDF

Info

Publication number
HRP960315A2
HRP960315A2 HR114458A HRP960315A HRP960315A2 HR P960315 A2 HRP960315 A2 HR P960315A2 HR 114458 A HR114458 A HR 114458A HR P960315 A HRP960315 A HR P960315A HR P960315 A2 HRP960315 A2 HR P960315A2
Authority
HR
Croatia
Prior art keywords
preparation according
peptide
phospholipids
cell
val6
Prior art date
Application number
HR114458A
Other languages
English (en)
Croatian (hr)
Inventor
Irun R Cohen
Dana Elias
Meir Shinitzky
Original Assignee
Yeda Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yeda Res & Dev filed Critical Yeda Res & Dev
Publication of HRP960315A2 publication Critical patent/HRP960315A2/hr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Synthetic bilayered vehicles, e.g. liposomes or liposomes with cholesterol as the only non-phosphatidyl surfactant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A61K9/0029—Parenteral nutrition; Parenteral nutrition compositions as drug carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Obesity (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Marine Sciences & Fisheries (AREA)
HR114458A 1995-07-05 1996-07-04 Preparations and methods for the treatment of t cell mediated diseases HRP960315A2 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
IL11445895A IL114458A0 (en) 1995-07-05 1995-07-05 Therapeutic preparations for treatment of T cell mediated diseases

Publications (1)

Publication Number Publication Date
HRP960315A2 true HRP960315A2 (en) 1998-02-28

Family

ID=11067727

Family Applications (1)

Application Number Title Priority Date Filing Date
HR114458A HRP960315A2 (en) 1995-07-05 1996-07-04 Preparations and methods for the treatment of t cell mediated diseases

Country Status (22)

Country Link
EP (1) EP0837672B9 (fr)
JP (2) JP4357595B2 (fr)
KR (1) KR100435040B1 (fr)
CN (1) CN1102382C (fr)
AT (1) ATE254451T1 (fr)
AU (1) AU714970B2 (fr)
CA (1) CA2226013C (fr)
CZ (1) CZ298A3 (fr)
DE (1) DE69630787T2 (fr)
DK (1) DK0837672T3 (fr)
ES (1) ES2211963T3 (fr)
HR (1) HRP960315A2 (fr)
HU (1) HU223081B1 (fr)
IL (2) IL114458A0 (fr)
MX (1) MX9800190A (fr)
NO (1) NO320363B1 (fr)
PT (1) PT837672E (fr)
SI (1) SI0837672T1 (fr)
UY (1) UY24275A1 (fr)
WO (1) WO1997002016A1 (fr)
YU (1) YU40796A (fr)
ZA (1) ZA965666B (fr)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5993803A (en) * 1996-08-30 1999-11-30 Yeda Research And Development Co., Ltd. Method of reducing the severity of host vs graft reaction by down-regulating hsp60 autoimmunity
US6022697A (en) 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
US7572631B2 (en) 2000-02-24 2009-08-11 Invitrogen Corporation Activation and expansion of T cells
US7541184B2 (en) 2000-02-24 2009-06-02 Invitrogen Corporation Activation and expansion of cells
IL142536A0 (en) * 2001-04-11 2002-03-10 Yeda Res & Dev Carriers for therapeutic preparations for treatment of t-cell mediated diseases
WO2003096967A2 (fr) 2002-05-21 2003-11-27 Yeda Research And Development Co. Ltd. Vaccins d'adn codant des proteines de choc thermique
US20050084967A1 (en) 2002-06-28 2005-04-21 Xcyte Therapies, Inc. Compositions and methods for eliminating undesired subpopulations of T cells in patients with immunological defects related to autoimmunity and organ or hematopoietic stem cell transplantation
WO2004098489A2 (fr) * 2003-05-12 2004-11-18 Peptor Ltd. Compositions et procedes de modulation d'epitopes de hsp60 specifiques
WO2005048914A2 (fr) * 2003-11-24 2005-06-02 Yeda Research & Development Co. Ltd. Vaccins d'adn codant pour des fragments de peptide hsp60 permettant de traiter les maladies auto-immunes
EP1835933A4 (fr) 2005-01-04 2015-01-07 Yeda Res & Dev Hsp60, peptides hsp60 et vaccins a base de lymphocytes t pour immunomodulation
EP1945246A4 (fr) 2005-09-22 2009-03-11 Irun R Cohen Fragments immunogènes de domaines constants du récepteur de lymphocytes t et peptides dérivés de ceux-ci
JP2019523633A (ja) * 2016-04-29 2019-08-29 アライム ファーマシューティカルズ，インコーポレーテッド 組織の損傷に関連した疾患及び障害を予防及び治療する組織保護ペプチド

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4395394A (en) * 1979-10-26 1983-07-26 Pfizer Inc. Use of lipid amines formulated with fat or lipid emulsions as vaccine adjuvants
IL63734A (en) * 1981-09-04 1985-07-31 Yeda Res & Dev Lipid fraction,its preparation and pharmaceutical compositions containing same
SE8405493D0 (sv) * 1984-11-01 1984-11-01 Bror Morein Immunogent komplex samt sett for framstellning derav och anvendning derav som immunstimulerande medel
US5114844A (en) * 1989-03-14 1992-05-19 Yeda Research And Development Co., Ltd. Diagnosis and treatment of insulin dependent diabetes mellitus
IL97709A (en) * 1990-03-30 2005-05-17 Brigham & Womens Hospital Use of an mbp peptide for the preparation of a medicament for the treatment of multiple sclerosis

Also Published As

Publication number Publication date
SI0837672T1 (en) 2004-04-30
HU223081B1 (hu) 2004-03-29
PT837672E (pt) 2004-03-31
DE69630787T2 (de) 2004-10-07
UY24275A1 (es) 2000-12-29
CZ298A3 (cs) 1998-06-17
AU6484496A (en) 1997-02-05
JP4357595B2 (ja) 2009-11-04
YU40796A (sh) 1998-11-05
ATE254451T1 (de) 2003-12-15
IL122755A0 (en) 1998-08-16
JP2009242412A (ja) 2009-10-22
MX9800190A (es) 1998-04-30
DK0837672T3 (da) 2004-03-22
ES2211963T3 (es) 2004-07-16
EP0837672A4 (fr) 1999-01-27
NO980013D0 (no) 1998-01-02
CN1102382C (zh) 2003-03-05
DE69630787D1 (de) 2003-12-24
IL122755A (en) 2004-07-25
JPH11508899A (ja) 1999-08-03
CA2226013C (fr) 2012-09-18
HUP9802834A2 (hu) 1999-03-29
EP0837672A1 (fr) 1998-04-29
NO320363B1 (no) 2005-11-28
EP0837672B9 (fr) 2005-06-15
ZA965666B (en) 1997-01-27
NO980013L (no) 1998-02-19
AU714970B2 (en) 2000-01-13
EP0837672B1 (fr) 2003-11-19
CN1193907A (zh) 1998-09-23
WO1997002016A1 (fr) 1997-01-23
CA2226013A1 (fr) 1997-01-23
HUP9802834A3 (en) 2001-08-28
KR19990028738A (ko) 1999-04-15
KR100435040B1 (ko) 2004-08-18
IL114458A0 (en) 1995-11-27

Similar Documents

Publication Publication Date Title
Vaarala et al. Development of immune response to cow's milk proteins in infants receiving cow's milk or hydrolyzed formula
JP2009242412A (ja) Ｔ細胞介在の病気を治療するための製剤と方法
US20140134196A1 (en) Vaccine and method for treatment of neurodegenerative diseases
JP4256474B2 (ja) 宿主ｖｓ移植片反応の重篤度をＨＳＰ６０自己免疫性をダウンレギュレーションすることにより低下させる方法
PL184145B1 (pl) Analogi peptydu p277, środek diagnostyczny do diagnozowania IDDM, sposób wykrywania IDDM, środek farmaceutyczny do leczenia lub zapobiegania IDDM
HUP0001960A2 (hu) Metotrexát kombináció autoimmun tünetek befolyásolására
MXPA98000190A (en) Preparations and methods for the treatment of medium diseases by cellula
WO1997002016A9 (fr) Preparations et procedes de traitments de maladies mediees par les lymphocytes t
WO1998008536A9 (fr) Methode de reduction de la gravite d'une reaction de l'hote contre le greffon par regulation negative de l'autoimmunite vis-a-vis de hsp60
CA2320044A1 (fr) Traitement de la sclerose en plaques en utilisant le cop-1 et les cytokines de renforcement des th2
US20030190323A1 (en) Preparations and methods for the treatment of T cell mediated diseases
KR20030096311A (ko) 항원 담체로서 유용한 항염증성 지방 알콜 및 지방산에스테르
US6309847B1 (en) Method for detecting or monitoring the effectiveness of treatment of T cell mediated diseases
US6488933B2 (en) Preparations for the treatment of T cell mediated diseases
JP3905126B2 (ja) Ｔ細胞媒介疾患の治療の効力を検出又は監視する方法
US11400131B2 (en) Multi-peptide composition
Burrows et al. Oral administration of PPC enhances antigen-specific CD8+ T cell responses while reducing IgE levels in sensitized mice
JPH08500823A (ja) レトロウィルス関連神経疾患のバイスタンダー抑制
DAVID Oral Tolerance for the Treatment of Autoimmune Disease
JP2003512435A5 (fr)
Hafter et al. Oral Tolerance for the Treatment of Autoimmune Disease
HAFLER et al. I. OVERVIEW OF HUMAN AUTOIMMUNE DISEASE
Loewenbrück Dynamics in the cytokine profile of beta-amyloid-specific human T cells

Legal Events

Date Code Title Description
A1OB Publication of a patent application
AIPI Request for the grant of a patent on the basis of a substantive examination of a patent application
OBST Application withdrawn